Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?

Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?

Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches...

Full description

Bibliographic Details
Main Authors:	Lin Ma, Liufu Deng, Jianfeng Peng, Jinming Yu, Xiangjiao Meng
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2023-12-01
Series:	Cancer Biology & Medicine
Subjects:	locally advanced non-small cell lung cancer (la-nsclc) radiotherapy immunotherapy new regimen challenges
Online Access:	https://www.cancerbiomed.org/content/20/12/1035

Similar Items

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
by: Lorenzo Belluomini, et al.
Published: (2019-01-01)

Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
by: Leilei Wu, et al.
Published: (2023-05-01)

Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis
by: Jian Qin, et al.
Published: (2023-05-01)

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
by: Yang Liu, et al.
Published: (2018-08-01)

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
by: Chen Jie, et al.
Published: (2023-02-01)

Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report
by: Xianghua Ye, et al.
Published: (2022-02-01)

Radiotherapy and Immunotherapy in Lung Cancer
by: Kristin Hsieh, et al.
Published: (2023-06-01)

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Gen Lin, et al.
Published: (2024-02-01)

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
by: Johan F. Vansteenkiste, MD, PhD, et al.
Published: (2024-03-01)

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
by: Yu Chen, et al.
Published: (2020-07-01)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
by: Xiaofei Zhang, et al.
Published: (2023-02-01)

Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation
by: Jianfeng Peng, et al.
Published: (2021-09-01)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
by: Ou Yamaguchi, et al.
Published: (2019-04-01)

Combination of immunotherapy-radiotherapy in non-small cell lung cancer: Reality and perspective
by: Bouchra Amaoui, et al.
Published: (2021-12-01)

Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases
by: Judith Porte, et al.
Published: (2022-09-01)

Management of metastatic apocrine hidradenocarcinoma with chemotherapy and radiation
by: Daniel H. Miller, et al.
Published: (2015-10-01)

Comparative effectiveness and toxicity of radiotherapy regimens in limited stage small cell lung cancer: A network meta‐analysis
by: Jiupeng Zhou, et al.
Published: (2022-11-01)

Immune-checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients
by: Haryati, et al.
Published: (2020-01-01)

Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature
by: Alessio Bruni, et al.
Published: (2023-01-01)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
by: Lu Meng, et al.
Published: (2021-09-01)

Challenges in synergizing radiotherapy with immunotherapy to unlock the abscopal effect in metastatic NSCLC: A systematic review
by: Jason Liu, et al.
Published: (2023-09-01)

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
by: Shijie Shang, et al.
Published: (2021-11-01)

Three Weekly Versus Weekly Cisplatin: Comparison of two Different Chemotherapy Protocols with Concurrent Radiotherapy in Locally Advanced Head and Neck Cancer
by: Sankalp Singh, et al.
Published: (2022-05-01)

Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China
by: Shujie Zhou, et al.
Published: (2023-01-01)

Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial
by: Henrik Horndalsveen, et al.
Published: (2023-03-01)

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
by: Lucheng ZHU, et al.
Published: (2021-05-01)

IMRT in the treatment of locally advanced or inoperable NSCLC in the pre-durvalumab era: clinical outcomes and pattern of relapses, experience from the Oscar Lambret Center
by: Thomas Le Roy, et al.
Published: (2023-09-01)

Research Progress on Combination of Radiotherapy and Immunotherapy on Advanced Non-small Cell Lung Cancer with Negative Driver Genes
by: LI Peng, et al.
Published: (2023-09-01)

Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature Review
by: Massimiliano Cani, et al.
Published: (2022-12-01)

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
by: Chengli Du, et al.
Published: (2023-12-01)

Editorial: Factors that impact the survival of non-small cell lung cancer
by: Fiona Hegi-Johnson, et al.
Published: (2023-02-01)

Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience
by: Michael C. Tjong, et al.
Published: (2022-01-01)

Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: “MTD” or “ALARA”?
by: Nitin Ohri, et al.
Published: (2017-09-01)

A Review of Scheduling Strategies for Radiotherapy and Immune Checkpoint Inhibition in Locally Advanced Rectal Cancer
by: Lydia Melissourgou-Syka, et al.
Published: (2023-11-01)

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
by: Giuseppe Bronte, et al.
Published: (2023-08-01)

Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
by: ZHU Kuikui, et al.
Published: (2021-10-01)

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
by: Zi‐Chao Zhou, et al.
Published: (2022-08-01)

Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy
by: Osama Mohamad, et al.
Published: (2018-07-01)

The role of chemoradiotherapy and immunotherapy in stage III NSCLC
by: Zsuzsanna Orosz, et al.
Published: (2024-04-01)

Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
by: Barbara Melosky
Published: (2017-12-01)